PCOS Renamed PMOS To Reflect Broader Endocrine And Metabolic Burden
A Lancet paper on May 12 renamed PCOS to PMOS to emphasize endocrine and metabolic causes, aiming to improve diagnosis, care and research funding.
Associated PressThe condition PCOS is now called PMOS. What to know about the name change and what it means for care
TIME MagazineThe Condition Known as PCOS Has a New Name
FOX NewsName of common medical condition could be misleading patients, experts warn
The Guardian‘Unprecedented’ global effort gives new name to polycystic ovary syndrome – and new hope to millions of women
Overview
A paper published in The Lancet on May 12 announced that polycystic ovary syndrome will be renamed polyendocrine metabolic ovarian syndrome, or PMOS, after 14 years of collaboration.
Experts said the old name implied ovarian cysts and obscured the condition’s broader endocrine and metabolic effects, contributing to missed diagnoses and inadequate care.
The renaming was led by Prof Helena Teede and supported by Dr. Melanie Cree and an international coalition that included 56 academic, clinical and patient organizations and input from more than 14,000 people.
PMOS affects one in eight women—about 170 million people worldwide—and is linked to higher risks of Type 2 diabetes, heart disease and other metabolic problems, with insulin resistance affecting about 85% of those with the condition according to sources.
A global implementation strategy is underway and the authors expect the new name to be introduced into international guidelines and the International Classification of Diseases in 2028.
Analysis
Center-leaning sources frame the renaming favorably by emphasizing accuracy and improved patient care, foregrounding expert endorsements while omitting dissenting views. Editorial choices—a benefits-focused lead, selection of supportive expert quotes, and absence of counterarguments or patient skepticism—produce a cumulative pro-change narrative that normalizes the new PMOS terminology.